Tempus AI (NASDAQ:TEM) Stock Keeps Buy Rating at BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reaffirmed by BTIG Research in a note issued to investors on Monday, Benzinga reports. They currently have a $80.00 target price on the stock. BTIG Research‘s price objective indicates a potential upside of 22.60% from the company’s previous close.

TEM has been the topic of a number of other research reports. Guggenheim raised their price target on shares of Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Cantor Fitzgerald assumed coverage on shares of Tempus AI in a report on Wednesday, September 2nd. They set an “overweight” rating and a $80.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Tempus AI in a research report on Monday, September 21st. They set a “neutral” rating and a $75.00 price target for the company. Stifel Nicolaus reduced their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Finally, Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and upped their price target for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. Eleven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $72.47.

Tempus AI Stock Performance

Shares of NASDAQ TEM traded down $2.36 during trading on Monday, reaching $65.25. 842,535 shares of the company traded hands, compared to its average volume of 6,162,801. The firm has a 50 day simple moving average of $69.24 and a 200-day simple moving average of $57.26. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The stock has a market capitalization of $11.77 billion, a PE ratio of -45.24 and a beta of 3.54. Tempus AI has a 52-week low of $40.77 and a 52-week high of $93.38.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.22) EPS. Equities research analysts anticipate that Tempus AI will post -1.43 earnings per share for the current year.

Insider Activity

In other news, CEO Eric Lefkofsky sold 250,000 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the completion of the sale, the chief executive officer owned 100,000 shares of the company’s stock, valued at $7,747,000. This represents a 71.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total value of $49,000.00. Following the completion of the sale, the chief executive officer owned 15,874 shares of the company’s stock, valued at approximately $1,111,180. The trade was a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,280,965 shares of company stock worth $80,397,564. Company insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEM. Guardian Partners Inc. grew its position in shares of Tempus AI by 8.3% in the 3rd quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock worth $213,000 after buying an additional 200 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in shares of Tempus AI in the 3rd quarter worth approximately $27,000. Cyndeo Wealth Partners LLC grew its position in shares of Tempus AI by 6.7% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock worth $525,000 after buying an additional 400 shares during the last quarter. Arkadios Wealth Advisors grew its position in shares of Tempus AI by 9.6% in the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock worth $224,000 after buying an additional 435 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Tempus AI by 54.3% during the third quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock worth $101,000 after acquiring an additional 436 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.